Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Epigenetic checkpoints regulate the fate and function of CAR-T cells

Nature Immunology volume 25, pages 4–6 (2024)Cite this article

Subjects

T cells exist in many functional states, and dynamic transitions from one state to another affect the outcome of adoptive T cell therapy. FOXP1 and KLF2 are now identified as transcriptional regulators of the stemness of CD8+ CAR-T cells and the bifurcation of stem-like CD8+ CAR-T cells into effector and exhausted subsets, respectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: FOXP1 and KLF2 are key regulators of CAR-T cell fate.

References

  1. Jiang, P. et al. Leukemia 36, 2656–2668 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Riegel, D. et al. Mol. Cell 83, 622–636.e10 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Zhu, Z. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01685-w (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tsui, C. et al. Nature 609, 354–360 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Locke, F. L. et al. Lancet Oncol. 20, 31–42 (2019).

    Article  CAS  PubMed  Google Scholar 

  6. Qi, C. et al. Nat. Med. 28, 1189–1198 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen, G. M. et al. Cancer Discov. 11, 2186–2199 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gueguen, P. et al. Sci Immunol. 6, eabd5778 (2021).

    Article  CAS  PubMed  Google Scholar 

  9. Arcangeli, S. et al. J. Clin. Invest. 132, e150807 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Melenhorst, J. J. et al. Nature 602, 503–509 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. You, L. et al. Front. Immunol. 11, 1787 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gambacorta, V. et al. Cancer Discov. 12, 1449–1461 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Monica Casucci

  2. Università Vita-Salute San Raffaele, Milano, Italy

    Chiara Bonini

  3. Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

    Chiara Bonini & Eliana Ruggiero

Authors
  1. Monica Casucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Bonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eliana Ruggiero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eliana Ruggiero.

Ethics declarations

Competing interests

M.C., C.B. and E.R. are inventors on different patents on cancer immunotherapy and genome editing (E.R.: PCT/EP2018/060477, PCT/EP2019/079916 and PCT/EP2022/053040; C.B.: PCT/IT2006/000600, 12/927,292, PCT/US2014/031360, PCT/IB2015/057049, PCT/EP2018/060477, PCT/EP2019/079916, PCT/EP2021/061198 and PCT/EP2022/053040; M.C.: PCT/IB2015/057049, PCT/EP2021/061198 and PCT/EP2019/069712). M.C. has received research support from Kite/Gilead. C.B. has been a member of advisory boards and a consultant for Intellia Therapeutics, TxCell, Novartis, GSK, Allogene, Kite/Gilead, Miltenyi, Kiadis and Janssen, and received research support from Intellia Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Casucci, M., Bonini, C. & Ruggiero, E. Epigenetic checkpoints regulate the fate and function of CAR-T cells. Nat Immunol 25, 4–6 (2024). https://doi.org/10.1038/s41590-023-01708-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-023-01708-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing